Medicare AdvantageCoverageLow impact
MA08.160a, Ublituximab-xiiy (Briumvi ®) for intravenous use
Independence Blue Cross·Neurology, Rheumatology, Oncology +1 more·Pharmacy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.160a for Ublituximab-xiiy (Briumvi®) intravenous treatment has been reissued and will be effective July 9, 2025. This is a pharmacy policy update that may affect coverage criteria or prior authorization requirements for this specialty medication used in treating certain autoimmune conditions.
Action Required
By July 9, 2025: Billing team should review the complete policy details at the source URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Ublituximab-xiiy (Briumvi®). Update any relevant billing protocols or prior authorization workflows as needed once full policy details are available.